Gleolan
Phase 3Small molecule
Gleolan is one of 78 small molecule programs targeting Meningioma. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Nolvadex
AstraZenecaPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Taxotere
AAvyxa
Phase 3
Vepesid
AAvyxa
Phase 3
Yondelis
AApotex Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gleolan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNX Development Corp